Surgery Partners Posts Q3 Loss, Suspends Guidance Ahead of $25/Share HealthSpan Deal
SGRY has more than doubled off its 52-week low of $11.41 on elevated volume (4.4× avg).
Summary
Surgery Partners reported a $21.1M Q3 net loss on revenue of $815.3M and suspended guidance and its earnings call due to the pending HealthSpan buyout at $25.00 per share in cash.
Key Events · Earnings and Guidance · SGRY
-
Q3 Revenue Slips, Net Loss Widens
Revenue fell 0.8% to $815.3M from $821.5M, and net loss attributable to Surgery Partners was $21.1M (-$0.16 per share) versus -$22.7M a year earlier.
-
Adjusted EBITDA Declines
Adjusted EBITDA was $132.7M versus $136.4M in Q3 2025, a 16.3% margin; same-facility revenue grew 6.0% on 0.2% case growth.
-
Guidance and Earnings Call Suspended
Citing the pending HealthSpan transaction, the company will not host an earnings call and will no longer provide forward-looking guidance.
-
Balance Sheet and Leverage
Cash was $354.5M with $692.8M of revolver capacity at September 30, 2026; net debt to EBITDA was approximately 4.4x under the credit agreement.
Analysis · SGRY · Industrial Applications And Services
The merger headline was already out this morning, but the attached release carries the actual Q3 numbers: revenue slipped 0.8% to $815.3M and the company swung to a $21.1M net loss attributable to shareholders, with Adjusted EBITDA down to $132.7M from $136.4M. Management also stopped giving forward guidance and canceled the earnings call because of the pending takeover. That matters less for standalone valuation now — the $25.00 cash price is the anchor — and more as a check on whether the deal holds: same-facility revenue grew 6.0%, leverage sits at roughly 4.4x, and the amended agreement adds a 10% annual ticking fee if the merger has not closed by March 1, 2027, which puts pressure on both sides to finish in Q1 2027.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGRY was trading at $26.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $11.41 to $27.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.